Life Sciences

  • June 09, 2025

    Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ.

    The Federal Circuit on Monday upheld the validity of an Acadia Pharmaceuticals Parkinson's disease drug patent, saying the result was compelled by double-patenting precedent the court set last year, but generics maker MSN Laboratories has suggested it may seek en banc review.

  • June 09, 2025

    RFK Jr. Fires CDC's Entire 17-Member Vaccine Advisory Panel

    The U.S. Department of Health and Human Services announced Monday that Secretary Robert F. Kennedy Jr. removed every member of the committee that provides advice and guidance on the use of vaccines to the Centers for Disease Control and Prevention, pledging to replace them with his preferred picks.

  • June 09, 2025

    Chinese Student Accused Of Smuggling Roundworms To US

    A Chinese student pursuing a doctoral degree in Wuhan has been charged with smuggling roundworms to recipients associated with a University of Michigan laboratory and lying to federal agents about it, according to an announcement Monday by the U.S. Attorney's Office for the Eastern District of Michigan. 

  • June 09, 2025

    Gov't Seeks $706M Penalty In FCA Case Against Omnicare, CVS

    The government asked a New York federal judge to impose a collective $706 million in civil penalties on Omnicare Inc. and its parent, CVS Health Corp., after a jury found that they submitted millions of false billing claims for healthcare programs.

  • June 09, 2025

    Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments

    The Patent Trial and Appeal Board rightly held that amended claims of a Cardiovalve Ltd. heart valve implant aren't invalid, the Federal Circuit affirmed Monday.

  • June 09, 2025

    Investment Firm Lead Admits To Insider Trading Biotech Stock

    The former head of equity trading at Denver-based capital markets firm Irving Investors LLC admitted to receiving insider information on multiple companies and using that nonpublic knowledge to guide trading decisions to make an unlawful $220,912 profit, Connecticut U.S. Attorney David X. Sullivan announced.

  • June 09, 2025

    5th Amendment Can't Shield Ex-Exec, Drugmakers Argue

    Generic-drug makers urged a Pennsylvania court to compel a former executive to sit for a deposition in ongoing price-fixing litigation despite his invocation of the Fifth Amendment, arguing his testimony is crucial to their defense.

  • June 09, 2025

    Fitch Even's Ex-IP Client Wants Firm's Patent Suit Tossed

    Prenatal-Hope Inc. and its chief executive officer are asking an Illinois federal judge to dismiss a suit in which law firm Fitch Even Tabin & Flannery LLP seeks a declaration that the CEO isn't the inventor behind a prenatal test patent.

  • June 09, 2025

    Sheppard Mullin Adds Perkins Coie IP Trio In DC, Chicago

    Three Perkins Coie LLP intellectual property partners with deep experience representing clients in the pharmaceutical, biotechnology and related industries have jumped to Sheppard Mullin Richter & Hampton LLP.

  • June 09, 2025

    AI-Powered Cancer Diagnostics Firm Targets $400M IPO

    Caris Life Sciences Inc., a developer of artificial-intelligence enhanced cancer diagnostic tests, on Monday launched plans for an estimated $400 million initial public offering, represented by Latham & Watkins LLP and underwriters counsel Cooley LLP.

  • June 09, 2025

    HI Gov. Eyes Veto Of Medical Pot Bill Over Privacy Concerns

    Hawaii Gov. Josh Green has signaled that he intends to veto a bill modifying the state's medical marijuana program, saying that it would impinge the privacy rights of the Aloha State's medical cannabis patients.

  • June 09, 2025

    Rite Aid Gets Stay Of Appeals From Its Earlier Bankruptcy

    The New Jersey bankruptcy judge overseeing Rite Aid's current insolvency case pressed pause Monday on appeals of orders he entered last year in the drugstore chain's previous Chapter 11.

  • June 09, 2025

    Legal, Compliance Heads Named In Mallinckrodt-Endo Merger

    Ahead of finalizing their $6.7 billion merger, Ireland's Mallinckrodt PLC and Pennsylvania-based Endo Inc. announced that Mallinckrodt's current chief legal officer and Endo's chief compliance officer will be a part of the executive team that will drive the formation of what the companies said will be a global pharmaceutical industry leader.

  • June 09, 2025

    Husch Blackwell Hires 5 Quarles & Brady Life Sciences Pros

    Amid its efforts to grow in the life sciences space, Husch Blackwell LLP announced Monday that it has brought on three lawyers and two non-attorney professionals from Quarles & Brady LLP.

  • June 06, 2025

    Masimo Fights Ex-CEO's Bid To Ax Suit Over $450M Demand

    Masimo Corp. fought back against founder Joe Kiani's motion to dismiss the company's Delaware Chancery Court suit seeking a declaration that he's not due a $450 million payout after his ouster as CEO, arguing that bid is an "improper attempt to evade" the Delaware court's jurisdiction.

  • June 06, 2025

    Patent Office Leader Rejects IPRs Based On 12-Year Wait

    Acting U.S. Patent and Trademark Office Director Coke Morgan Stewart on Friday turned away a series of challenges to Welch Allyn Inc.'s heart monitor patents, determining petitioner iRhythm Technologies Inc. should have disputed them much earlier.

  • June 06, 2025

    Circle's Smash IPO Could Pave Way For More Crypto Listings

    Stablecoin issuer Circle's explosive debut will likely stimulate more crypto listings and possibly jolt the broader pipeline of initial public offerings, capital markets attorneys say.

  • June 06, 2025

    Justices Reject Eligibility Appeal On Telemedicine Patents

    The U.S. Supreme Court declined Friday to review a decision that telemedicine patents asserted against the U.S. government are invalid for claiming only abstract ideas, in the court's latest refusal to reconsider the standard for determining if inventions are eligible for patents.

  • June 06, 2025

    J&J Unit's $147M Catheter Antitrust Loss Tripled To $442M

    Johnson & Johnson health tech unit Biosense Webster's bill in an antitrust trial was upped from $147 million to $442 million after a California federal jury found it stifled competition by conditioning the provision of cardiac mapping services on purchases of cardiac catheters.

  • June 06, 2025

    Pharma Co. Trade Secrets Case Stays In Fla. Despite HQ Move

    A Florida federal judge on Friday denied a bid to toss a pharmaceutical company's lawsuit accusing a rival of stealing trade secrets because its headquarters moved to the Sunshine State after its initial complaint, saying there was "complete diversity at the time of filing of action."

  • June 06, 2025

    Rite Aid Emphasizes It Will Pay Rent To Objecting Landlords

    The twice-bankrupt drug store chain Rite Aid is seeking to reassure landlords who filed a spate of objections in recent days that it intends to continue meeting lease obligations despite its move to close some locations.

  • June 06, 2025

    Genentech Wants $18M Novartis Award Over Licenses OK'd

    California-based biotech firm Genentech Inc. has asked a D.C. federal court to recognize a $17.8 million arbitral award against Novartis Pharma AG stemming from a dispute over a licensing agreement for an eye medication.

  • June 06, 2025

    Fed. Circ. Weighs Purview Over Acorda's $17M Arbitral Award

    A Federal Circuit panel on Friday wrestled with its authority to consider arbitration appeals dealing with patent law, with at least one judge appearing skeptical that it could consider Acorda Therapeutics Inc.'s bid to increase a $16.6 million award in a fight with Alkermes PLC over a multiple sclerosis drug.

  • June 06, 2025

    CVS Health Can't Dodge Blame In Omnicare False Claims Suit

    A New York federal judge rebuffed an attempt from CVS Health Corp. to evade responsibility in a False Claims Act case, after a jury found that its subsidiary Omnicare bilked the federal government out of over $135 million in fraudulent drug claims. 

  • June 06, 2025

    Stewart Says PTAB Should 'Never' Cancel IP As A Sanction

    The acting director of the U.S. Patent and Trademark Office revived Longhorn Vaccines & Diagnostics LLC patent claims on Thursday that her predecessor had invalidated to punish Longhorn for misconduct.

Expert Analysis

  • Series

    Playing Guitar Makes Me A Better Lawyer

    Author Photo

    Being a lawyer not only requires logic and hard work, but also belief, emotion, situational awareness and lots of natural energy — playing guitar enhances all of these qualities, increasing my capacity to do my best work, says Kosta Stojilkovic at Wilkinson Stekloff.

  • Crisis Management Lessons From The Parenting Playbook

    Author Photo

    The parenting skills we use to help our kids through challenges — like rehearsing for stressful situations, modeling confidence and taking time to reset our emotions — can also teach us the fundamentals of leading clients through a corporate crisis, say Deborah Solmor at the Wisconsin Alumni Research Foundation and Cara Peterman at Alston & Bird.

  • Justices' Labcorp Questions Explore Class Cert. Tensions

    Author Photo

    At the recent oral argument before the U.S. Supreme Court in Laboratory Corporation of America Holdings v. Davis, the justices' questioning highlighted a fundamental tension between constitutional standing requirements, the procedural framework of Rule 23, and the practical challenges of managing large, diverse classes in complex litigation, say attorneys at Winston & Strawn.

  • 4 Legislative Proposals Reflect Growing Scrutiny Of Pharma IP

    Author Photo

    Bipartisan legislative momentum in Congress, including a recent package of bills targeting exclusivity strategies that delay generic and biosimilar competition, signals growing scrutiny of life sciences intellectual property strategies, so biologics companies and investors must pay attention to new strategic, compliance and litigation risks, says Olga Berson at Thompson Coburn.

  • Series

    Adapting To Private Practice: From NY Fed To BigLaw

    Author Photo

    While the move to private practice brings a learning curve, it also brings chances to learn new skills and grow your network, requiring a clear understanding of how your skills can complement and contribute to a firm's existing practice, and where you can add new value, says Meghann Donahue at Covington.

  • 7 Considerations For Conducting Drug Clinical Trials Abroad

    Author Photo

    With continuing cuts to U.S. Food and Drug Administration staffing motivating some pharmaceutical companies to consider developing drugs abroad, it's important to understand the additional risks and compliance requirements associated with conducting clinical studies in other countries, say attorneys at Morgan Lewis.

  • Top 3 Litigation Finance Deal-Killers, And How To Avoid Them

    Author Photo

    Like all transactions, litigation finance deals can sometimes collapse, but understanding the most common reasons for failure, including a lack of trust or a misunderstanding of deal terms, can help both parties avoid problems, say Rebecca Berrebi at Avenue 33 and Boris Ziser at Schulte Roth.

  • 5th Circ. Ruling Is Latest Signal Of Shaky Qui Tam Landscape

    Author Photo

    In his recent concurring opinion in U.S. v. Peripheral Vascular Associates, a Fifth Circuit judge joined a growing list of jurists suggesting that the False Claims Act's whistleblower provisions are unconstitutional, underscoring that acceptance of qui tam relators can no longer be taken for granted, say attorneys at Miller & Chevalier.

  • How Attys Can Use A Therapy Model To Help Triggered Clients

    Author Photo

    Attorneys can lean on key principles from a psychotherapeutic paradigm known as the "Internal Family Systems" model to help manage triggered clients and get settlement negotiations back on track, says Jennifer Gibbs at Zelle.

  • 3 Steps For In-House Counsel To Assess Litigation Claims

    Author Photo

    Before a potential economic downturn, in-house attorneys should investigate whether their company is sitting on hidden litigation claims that could unlock large recoveries to help the business withstand tough times, says Will Burgess at Hilgers Graben.

  • J&J's Failed 3rd Try Casts Doubt On Use Of 'Texas Two-Step'

    Author Photo

    A Texas bankruptcy court recently rejected Johnson & Johnson's third attempt to use Chapter 11 to resolve liabilities from allegations of injuries from using talcum powder, suggesting that the U.S. Supreme Court's limitations on nondebtor releases, from 2024's Purdue Pharma ruling, may prove difficult to evade, say attorneys at Cadwalader.

  • Series

    Teaching College Students Makes Me A Better Lawyer

    Author Photo

    Serving as an adjunct college professor has taught me the importance of building rapport, communicating effectively, and persuading individuals to critically analyze the difference between what they think and what they know — principles that have helped to improve my practice of law, says Sheria Clarke at Nelson Mullins.

  • Why Attys Should Get Familiar With Quantum Computing

    Author Photo

    Quantum computing is projected to pose significant updates to current practices in cryptography, making the issue relevant to policymakers and the legal profession generally, particularly when it comes to data storage, privacy regulations and pharmaceutical industry market changes, say professors at the University of San Francisco.

  • Series

    Adapting To Private Practice: From DOJ Enviro To Mid-Law

    Author Photo

    Practitioners leaving a longtime government role for private practice — as when I departed the U.S. Department of Justice’s environmental enforcement division — should prioritize finding a firm that shares their principles, values their experience and will invest in their transition, says John Cruden at Beveridge & Diamond.

  • Legal Ethics Considerations For Law Firm Pro Bono Deals

    Author Photo

    If a law firm enters into a pro bono deal with the Trump administration in exchange for avoiding or removing an executive order, it has an ethical obligation to create a written settlement agreement with specific terms, which would mitigate some potential conflict of interest problems, says Andrew Altschul at Buchanan Angeli.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.